Resumen de: EP3485907A1

The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

Resumen de: WO2018015380A1

The present invention relates to means and method for isolating naturally-occurring microorganisms (non-pathogenic bacteria, yeasts or fungi) capable of binding toxins from microorganisms such as bacteria, viruses, fungi, yeasts, or protozoans and/or receptors for these toxins on the surface of mammalian cells, thereby making these receptors inaccessible for said toxins. The naturally-occurring microorganisms that are obtainable by the means and methods of the present invention can be used for adsorbing toxins from pathogenic microorganisms and/or blocking receptors for such toxins on the surface of mammalian cells. These toxin-receptor interactions are known to be critical for disease pathogenesis, making both the toxins and receptors a target for the naturally-occurring microorganisms of the present invention.

Resumen de: WO2018007562A1

The present invention relates to a method of reducing human salmonellosis due to consumption by contaminated food. More in particular, the present invention discloses a specific wheat bran fraction that reduces colonization of Salmonella bacteria in the gut of animals which are part of the human food chain. The present invention indeed demonstrates that animals such as broilers which are given feed supplemented with the latter feed bran fraction -and are then infected with Salmonella- have a significantly reduced number of Salmonella bacteria in their cecum and shed less bacteria in their environment when compared to control animals which are given non-supplemented feed.

Resumen de: US2019134177A1

The present investigation relates to a conjugate comprising flagellin adjuvant covalently linked to Vi polysaccharide derived from S. typhi for vaccination against typhoid. Both flagellin adjuvant and Vi polysaccharide are from S. typhi which leads to the improved immunogenicity. The conjugate of the present invention can be used as single dose administration without the need of multiple immunizations. The present invention also discloses a nanoparticle composition comprising the conjugate of the present invention.

Resumen de: US2019136293A1

Provided are compositions, kits, and methods for the identification of Salmonella. In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.

Resumen de: WO2014102503A1

The invention relates to a micro-organism detection medium, said detection being based on the discovery of a microbial enzymatic activity selected from esterase and/or osidase and/or peptidase and/or sulfatase and/or phosphatase activities of micro-organisms, preferably said microbial enzymatic activity being an esterase activity, said medium comprising: at least one chromogen and/or fluorogen substrate specific to the desired enzymatic activity, preferably specific to an esterase activity, at least one alkyl(thio)glycoside, and at least one solvent (S).

Resumen de: US2019137491A1

Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with P. copri or a portion thereof. In one aspect of the invention the immunological reactivity of the subject to one or more protein of P. copri or polypeptide fragments thereof such as protein Pc-p27 or polypeptide fragments thereof, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.

Resumen de: WO2014111516A1

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Resumen de: WO2011036564A2

Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.

Resumen de: WO2014111516A1

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Resumen de: WO2012012874A1

The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue, wherein the condition characterized by inflammation is not a cancer. In embodiments of the invention, a cancer is situated in the specific organ or tissue.

Resumen de: AU2017339841A1

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This discosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.

Resumen de: AU2017353327A1

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

Resumen de: AU2017342088A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

Resumen de: US2019125897A1

The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

Resumen de: WO2012145355A1

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Resumen de: US2019118174A1

The present invention refers to the in vitro use of a microfluidic kit or device comprising a support or substrate, wherein said support or substrate comprises at least one channel in the substrate, the channel comprising an inlet, an outlet, and a flow-path connecting the inlet and outlet, wherein the inlet and outlet together define a midplane; and a portion of the flowpath travels transversely across the midplane, wherein the portion of the flowpath that travels transversely across the midplane includes a recognition site or sensing area for detecting a target analyte; for detecting an analyte as a result of the heat generated by metal nanoparticles when they are irradiated with an external light source.

Resumen de: US2019120838A1

The present invention relates to methods and kits for the rapid detection of the Escherichia coli O25b-ST131 clone. The inventors have isolated a podoviridae bacteriophage (LM33_P1) infecting the E. coli strain LM33 isolated from ventilator associated pneumonia and which belongs to clone STI3I-025b. By testing different strains of E coli belonging to 129 others various distinct serotypes (including twelve O25a) the inventors found that bacteriophage LM33_P1 is able to infect exclusively O25b strains (none of non-O25b strains could be infected by LM33_P1). The inventors have determined that the specificity displayed by bacteriophage LM33_P1 to infect only 025b serotype strains is based on a very specific polypeptide (Gp17) used by LM33_P1 to attach the bacterial cell via LPS molecule. In particular, the present invention relates to a polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence set forth in SEQ ID NO:1.

Resumen de: US2019117755A1

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Resumen de: WO2019077109A1

The present invention refers to an immunogenic fragment of a protein comprising a sequence with at least a 95% identity with SEQ ID NO: 1, also wherein said fragment has a molecular weight of 2 to 120kDa; also to the use of a protein comprising a sequence with at least a 95% identity with SEQ ID NO: 1 or said fragment for use as immunogen. The invention also refers to an antibody that specifically binds to said protein or fragment thereof, and the uses of them in the treatment and/or prophylaxis of a bacterial infectious disease and as antibiotic resistance inhibitor.

Resumen de: WO2017216635A1

Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.

Resumen de: CN109663125A

本发明涉及微生物技术领域，特别涉及种禽用沙门氏菌疫苗，还涉及所述沙门氏菌的应用。种鸡肠炎沙门氏菌灭活疫苗,所述疫苗组合物包括鸡肠炎沙门氏菌液和佐剂，其中所述佐剂由以下重量份数的原料组成：水性油佐剂50份，司盘‑80 1.5‑3.5份，吐温‑80 1.5‑2.5份，小肽0.1份，蜂胶1.5‑2.5份。本发明的提供的沙门氏菌灭活疫苗针对性强，对当地流行的沙门氏菌菌株免疫效果好，制备工艺操作简单，成本较低，易于储存，适用于有实验室的规模性养殖场。

Resumen de: AU2017353432A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding Wilms' Tumor Protein (WT1), for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1,CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding WT1 for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1,CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.

Resumen de: US2019111121A1

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Resumen de: WO2017157434A1

The present specification discloses methods of detecting a Salmonella live vaccine bacteria of interest and components useful in carrying out these methods, including a first and second pre-enrichment media, and enrichment media and a detection solution.